SCHEMBL7085265

SCHEMBL7085265

CC(C)(C)c1ccccc1C(CNS(=O)(=O)N(C(=O)O)c1ccccc1)(c1ccccc1)C(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.35
RAB9A P51151 3/20 0.34
ALDH1A1 P00352 2/20 0.34
NPC1 O15118 1/20 0.34
RECQL P46063 1/20 0.34
LMNA P02545 1/20 0.32
CYP2D6 P10635 1/20 0.32
HDAC8 Q9BY41 2/20 0.32
HDAC3 O15379 1/20 0.32
HDAC11 Q96DB2 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
MAPK1 P28482 1/20 0.32
HTT P42858 1/20 0.32
RBP4 P02753 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
ALOX5 P09917 1/20 0.31
PTGS2 P35354 1/20 0.31
CYP1A2 P05177 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7081217 0.90 LMNA (0.34) CYP2C19LMNAALOX5PTGS2CYP3A4
SCHEMBL7080913 0.88 EPHX2 (0.38) RAB9AALDH1A1LMNAMEN1KMT2A
SCHEMBL7081978 0.72 CA2 (0.37) RAB9AALDH1A1NPC1RECQLMEN1
SCHEMBL7617674 0.72 ALDH1A1 (0.33) ALDH1A1LMNA
SCHEMBL7085259 0.69 METAP2 (0.39) ALDH1A1LMNA
SCHEMBL7081981 0.69 ACLY (0.36) CYP2C19ALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL7085484 0.67 ACLY (0.36) LMNA
SCHEMBL7085267 0.65 ALDH1A1 (0.36) CYP2C19ALDH1A1RBP4CYP1A2CYP3A4
SCHEMBL7081215 0.63 CYP1A2 (0.36) CYP2C19CYP1A2CYP3A4CYP2C9TSHR
SCHEMBL7081976 0.62 RBP4 (0.39) HTTRBP4NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0592439-B1 AMINOSULFONYL CARBAMATES WARNER LAMBERT CO (US) 2003-07-30 EP claimed
US-20030134898-A1 Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production HOMAN REYNOLD (US) 2003-07-17 US claimed
EP-1281399-A2 Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production WARNER-LAMBERT COMPANY (US) 2003-02-05 EP claimed
US-20020183384-A1 Methods of treating nuclear factor-kappa B mediated diseases and disorders CORNICELLI JOSEPH ANTHONY (US) 2002-12-05 US claimed
EP-1236468-A1 Sulfonylaminocarbonyl derivatives for the treatment of nuclear factor-kappa B mediated diseases and disorders WARNER-LAMBERT COMPANY (US) 2002-09-04 EP claimed
US-5336690-A Anticholesterol agents WARNER-LAMBERT COMPANY (US) 1994-08-09 US claimed
EP-0592439-A1 AMINOSULFONYL CARBAMATES WARNER-LAMBERT COMPANY (US) 1994-04-20 EP claimed
WO-1992008693-A1 AMINOSULFONYL CARBAMATES WARNER-LAMBERT COMPANY (US) 1992-05-29 WO claimed
EP-0592439-B1 AMINOSULFONYL CARBAMATES WARNER LAMBERT CO (US) 2003-07-30 EP disclosed
US-20030134898-A1 Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production HOMAN REYNOLD (US) 2003-07-17 US disclosed
EP-1281399-A2 Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production WARNER-LAMBERT COMPANY (US) 2003-02-05 EP disclosed
US-20020183384-A1 Methods of treating nuclear factor-kappa B mediated diseases and disorders CORNICELLI JOSEPH ANTHONY (US) 2002-12-05 US disclosed
EP-1236468-A1 Sulfonylaminocarbonyl derivatives for the treatment of nuclear factor-kappa B mediated diseases and disorders WARNER-LAMBERT COMPANY (US) 2002-09-04 EP disclosed
US-5336690-A Anticholesterol agents WARNER-LAMBERT COMPANY (US) 1994-08-09 US disclosed
EP-0592439-A1 AMINOSULFONYL CARBAMATES WARNER-LAMBERT COMPANY (US) 1994-04-20 EP disclosed
US-5254715-A Anticholesterol agents WARNER-LAMBERT COMPANY (US) 1993-10-19 US disclosed
WO-1992008693-A1 AMINOSULFONYL CARBAMATES WARNER-LAMBERT COMPANY (US) 1992-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183384-A1 Methods of treating nuclear factor-kappa B mediated diseases and disorders NFKBIA, IKBKB, RELA CYP2C19 4777/4885RAB9A 4119/4885ALDH1A1 4328/4885
US-20030134898-A1 Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production ACAT2, LCAT, SOAT1 CYP2C19 1110/4885RAB9A 4359/4885ALDH1A1 412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.